Hope remains despite failure of Lilly's solanezumab
from By Denise A. Valenti
High expectations and hopes surrounded Eli Lilly and Company's drug solanezumab. Solanezumab is a humanized monoclonal IbG1 antibody, and it was targeting an amyloid beta peptide with the goal of slowing the effects of Alzheimer's disease. The promise shown in early phases of research was not shown during a third phase of testing, Lilly announced recently. The company has no plans to seek regulatory approval for the drug. But hope is not lost.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063